Bluebird Bio, Inc. (BLUE) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Exhibit 99.1

bluebird bio Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Progress

-- Treated first patient in CRB-401 study of anti-BCMA CAR T bb2121 in relapsed/refractory multiple myeloma --

-- Announced that Celgene has exercised its option to license bb2121 --

-- Presented LentiGlobin clinical data in transfusion-dependent ß-thalassemia and severe sickle cell disease at the American Society of Hematology (ASH) annual meeting --

-- Presented pre-clinical and manufacturing data from oncology pipeline at ASH annual meeting --

-- Signed exclusive license agreement with Viromed for solid tumor CAR T target --

-- Ended year with $865.8 million in cash, cash equivalents, and marketable securities --

CAMBRIDGE, Mass., February 24, 2016 – bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2015.

“In 2015 bluebird bio defined an accelerated regulatory path for LentiGlobin in ß-thalassemia and established a powerful reason to believe in LentiGlobin in sickle cell disease, though there is still more to learn as we treat additional patients. We also fully enrolled our Starbeam study of Lenti-D in cerebral adrenoleukodystrophy and made significant advances in building a competitive T cell oncology franchise,” said Nick Leschly, chief bluebird. “In 2016 we are excited to learn even more across all of our programs and continue to innovate and improve. We are particularly looking forward to sharing data from the Starbeam study for the first time and presenting more data with longer follow-up from all three of our LentiGlobin clinical studies.”

Recent Highlights

1